Internal Medicine, Hematology & Oncology · Fresno, CA
NPI
1538244314
Since 2006
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
2
Hospital affiliations
7130 N Millbrook Ave
Fresno, CA, 93720
Phone (559) 326-1222
Groups this clinician bills Medicare through
Medicare paid, 2024
$4.7M
632,609 services
Medicare patients, 2024
951
Average age 75
Drug cost, 2024
$3.8M
1,567 prescriptions
Company payments, 2025
$969
From 19 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Joseph M Pascuzzo was code J0881 (injection, darbepoetin alfa, 1 microgram (non-esrd use)), 185,500 times for 151 patients. In total Joseph M Pascuzzo billed 632,609 services in 197 codes, and Medicare paid $4.7M.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2025-10-09.
| Code |
|---|
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0881 Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 185,500 | 151 | $2.31 | $428K |
| J1439 Injection, ferric carboxymaltose, 1 mg | Office | 141,750 | 107 | $0.87 | $123K |
| J1071 Injection, testosterone cypionate, 1 mg | Office | 114,400 | 32 | $0.02 | $2,014 |
| Q5125 Injection, filgrastim-ayow, biosimilar, (releuko), 1 microgram | Office | 27,780 | 13 | $0.37 | $10K |
| J0897 Injection, denosumab, 1 mg | Office | 17,040 | 82 | $20.51 | $350K |
| J1569 Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | Office | 11,180 | 19 | $35.78 | $400K |
| J9271 Injection, pembrolizumab, 1 mg | Office | 10,000 | 14 | $44.78 | $448K |
| J1437 Injection, ferric derisomaltose, 10 mg | Office | 9,500 | 87 | $15.65 | $149K |
| J0185 Injection, aprepitant, 1 mg | Office | 6,760 | 16 | $1.35 | $9,130 |
| Q9967 Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | Office | 6,500 | 72 | $0.10 | $656 |
| J1627 Injection, granisetron, extended-release, 0.1 mg | Office | 4,700 | 14 | $4.39 | $21K |
| 85025 Blood Count | Office | 2,741 | 633 | $7.59 | $21K |
| 36415 Venipuncture Blood Collection | Office | 2,737 | 632 | $8.65 | $24K |
| 80053 Clinical Chemistry | Office | 2,116 | 630 | $10.32 | $22K |
| 96372 Injection Administration | Office | 2,046 | 391 | $10.83 | $22K |
By year: 2022 $4.9M for 820,276 services; 2023 $4.9M for 722,400 services; 2024 $4.7M for 632,609 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 2,741 | 633 | $7.59 | $21K |
| 36415 Venipuncture Blood Collection | 2,737 | 632 | $8.65 | $24K |
| 80053 Clinical Chemistry | 2,116 | 630 | $10.32 | $22K |
| 83540 Clinical Chemistry | 1,643 | 600 | $6.32 | $10K |
| 83550 Clinical Chemistry | 1,643 | 600 | $8.54 | $14K |
| 82728 Clinical Chemistry | 1,609 | 598 | $13.31 | $21K |
| 85045 Blood Count | 611 | 312 | $3.88 | $2,371 |
| 83615 Clinical Chemistry | 253 | 165 | $5.92 | $1,498 |
| 82378 Clinical Chemistry | 234 | 112 | $18.37 | $4,298 |
| 84550 Clinical Chemistry | 229 | 137 | $4.43 | $1,014 |
Medicare prescription drug claims, 2024
In 2024, the drug Joseph M Pascuzzo prescribed most often to Medicare patients was Levothyroxine Sodium, with 166 prescriptions and refills. In total Joseph M Pascuzzo wrote 1,567 Medicare prescriptions that cost $3.8M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Levothyroxine Sodium Generic | 166 | 286 | 43 | $1,625 |
| Famotidine Generic | 110 | 177 | 32 | $860 |
| Ondansetron Odt Ondansetron | 86 | 86 | 42 | $2,150 |
| Letrozole Generic | 86 | 228 | 27 | $3,050 |
| Warfarin Sodium Generic | 68 | 126 | 16 | $431 |
| Potassium Chloride Generic | 62 | 72 | 20 | $1,266 |
| Prednisone Generic | 56 | 77 | 16 | $347 |
| Hydroxyurea Generic | 52 | 120 | 14 | $1,819 |
| Lenalidomide Generic | 47 | 47 | Under 11 | $772K |
| Megestrol Acetate Generic | 44 | 46 | 18 | $5,209 |
| Vancomycin Hcl Generic | 39 | 39 | Under 11 | $232 |
| Allopurinol Generic | 35 | 69 | 11 | $328 |
| Eliquis Apixaban | 33 | 53 | 11 | $29K |
| Dexamethasone Generic | 33 | 33 | Under 11 | $724 |
| Gabapentin Generic | 32 | 33 | Under 11 | $275 |
Brand drugs: - claims; generic drugs: 1,255 claims; opioid claims: 63.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Joseph M Pascuzzo $969 ($969 in general payments such as food, travel and fees) from 19 companies. The largest payer was AstraZeneca Pharmaceuticals LP with $199.
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP AZN | 8 | $199 |
| Exelixis Inc. EXEL | 5 | $116 |
| Novartis Pharmaceuticals Corporation NVS | 4 | $111 |
| SpringWorks Therapeutics, Inc. | 3 | $88.53 |
| Abbvie Inc. ABBV | 3 | $74.24 |
| Daiichi Sankyo Inc. 4568.T | 3 | $66.91 |
| Octapharma USA, Inc. | 1 | $45.45 |
| TerSera Therapeutics LLC | 1 | $32.6 |
| Tempus AI, Inc TEM | 1 | $28.17 |
| Ipsen Biopharmaceuticals, Inc IPN.PA | 1 | $26.07 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.